3,6-DMAD is an acridine derivative that selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM), but not eIF2a phosphorylation, by directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1α oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.).
3,6-DMAD is an acridine derivative.
3,6-DMAD is also called as N9-(3-(dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts.
Molecular cancer therapeutics, 15(9), 2055-2065 (2016-06-17)
Using a luciferase reporter-based high-throughput chemical library screen and topological data analysis, we identified N-acridine-9-yl-N',N'-dimethylpropane-1,3-diamine (DAPA) as an inhibitor of the inositol requiring kinase 1α (IRE1α)-X-box binding protein-1 (XBP1) pathway of the unfolded protein response. We designed a collection of
Acridine Derivatives as Inhibitors of the IRE1 alpha-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma
